Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasisulam in metastatic melanoma
NCT00383292Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2006
- Primary completion
- Sep 2011
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tasisulam in melanoma, sponsored by Eli Lilly and Company. Primary endpoint: Objective Response Rate up to 60 months. Started Nov 2006; status: completed.
02
Drugs
tasisulam
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00383292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383292.